DUBLIN--(BUSINESS WIRE)--The "Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Spinocerebellar Ataxia - Pipeline Review, H2 ...
orphan-drug-ro Portage Biotech and Biohaven Pharmaceutical announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to BHV-0223 for the treatment of spinocerebellar ...
The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare genetic ...
The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.
GAITHERSBURG, Md., Jan. 26, 2021 /PRNewswire/ -- GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced that ...
To report optical coherence tomography (OCT) findings in order to detect subclinical alterations of the afferent visual pathways in spinocerebellar ataxia 3 (SCA-3). Nine genetically confirmed ...
NEW HAVEN, Conn., May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and ...
SLS-005 contains the active ingredient trehalose, a low molecular weight disaccharide (0.342 kDa) that has been shown to penetrate muscle and cross the blood brain barrier. The Food and Drug ...
Ataxia is a degenerative disease affecting the nervous system, presenting poor coordination and movement, difficulties with speech, walking, fine motor skills, swallowing, and vision. It mainly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback